Lisa A. Prosser, Ph.D., M.S.
2800 Plymouth Road
Ann Arbor, MI 48109-2800
Dr. Prosser is the Marilyn Fisher Blanch Research Professor of Pediatrics and Director of the Susan B. Meister Child Health Evaluation and Research Center. Her research focuses on measuring the value of childhood health interventions using methods of decision sciences and economics. Current research topics include newborn screening programs, vaccination programs, and methods for valuing family spillover effects of illness. She also uses quantitative survey methods (health utility assessment, conjoint analysis) to measure health-related quality of life and preferences for health interventions.
Dr. Prosser's research evaluating the cost-effectiveness of vaccination programs has been used in setting national vaccine policy for children and adults. Her work with the Evidence Review Group for the Advisory Committee on Heritable Disorders in Newborns and Children using decision science modeling to project long-term health outcomes for proposed newborn screening programs has been used to inform national newborn screening policy decisions. She is currently a member of the evidence review group for the Advisory Committee on Heritable Disorders in Newborns and Children and the ACIP Zoster Working Group.
Dr. Prosser has contributed to faculty development programs at the department, school, and institutional level. She currently serves as the Associate Vice President for Research-Health Sciences. Dr. Prosser also holds an adjunct faculty appointment at the Harvard School of Public Health.
Ph.D., Health Policy (Concentration: Decision Sciences), Harvard University, 2000
M.S., Technology & Policy, Massachusetts Institute of Technology, 1992
M.S., Management, MIT Sloan School of Management, 1992
B.A., Mathematics (Concentration: Operations Research), Cornell University, 1988
- VoCHI - Cost-effectiveness analysis of Vaccination to Prevent COVID-19
- VoCHI - Eliciting Preferences and Weights for Equity and Efficiency: A Methodological Scoping Review
- Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) Evidence Review Group
- Deriving a Health State Classification System to Measure Health Utilities for Pediatric Populations Based on the PedsQL
- Estimating the economic burden of RSV infection and cost-effectiveness of a hypothetical RSV vaccine
- Evaluating Health and Economic Outcomes for Preventing Caries Risk in Underserved Children
- Joint Initiative in Vaccine Economics, Phase 6: Estimating the economic burden of RSV infection and cost-effectiveness of a hypothetical RSV vaccine (JIVE 6)
- Joint Initiative in Vaccine Economics, Phase 6: Estimating the quality of life lost due to COVID-19 illness and adult vs pediatric preferences for COVID-19 vaccination (JIVE 6)
Carlton EF, Weiss SL, Prescott HC, Prosser LA.
What's the Cost? Measuring the Economic Impact of Pediatric Sepsis
Frontiers in Pediatrics. 2021 Nov 15;9:761994. doi: 10.3389/fped.2021.761994. PMID: 34869119; PMCID: PMC8634593.
Grosse SD, Kemper AR, Prosser LA.
Data Needs for Economic Evaluations of Screening in Pediatric Primary Care: A Research Framework
Pediatrics. 2021 Jul;148(Suppl 1):s45-s50. doi: 10.1542/peds.2021-050693J. PMID: 34210848; PMCID: PMC8312553.
Chen HF, Rose AM, Waisbren S, Ahmad A, Prosser LA.
Newborn Screening and Treatment of Phenylketonuria: Projected Health Outcomes and Cost-Effectiveness
Children (Basel). 2021 May 12;8(5):381. doi: 10.3390/children8050381. PMID: 34065950; PMCID: PMC8151371.
Cernat A, Hayeems RZ, Prosser LA, Ungar WJ.
Incorporating Cascade Effects of Genetic Testing in Economic Evaluation: A Scoping Review of Methodological Challenges
Children (Basel). 2021 Apr 27;8(5):346. doi: 10.3390/children8050346. PMID: 33925765; PMCID: PMC8145875.
Richardson JS, Kemper AR, Grosse SD, Lam WKK, Rose AM, Ahmad A, Gebremariam A, Prosser LA.
Health and economic outcomes of newborn screening for infantile-onset Pompe disease
Genetics in Medicine. 2021 Apr;23(4):758-766. doi: 10.1038/s41436-020-01038-0. Epub 2020 Dec 7. PMID: 33281187; PMCID: PMC8035228.
Hutton DW, McCullough JS, Prosser L, Ye W, Herman WH, Zhang P, Pilishvili T, Pike J.
Costs implications of pneumococcal vaccination of adults aged 30-60 with a recent diagnosis of diabetes
Vaccine. 2021 Feb 22;39(8):1333-1338. doi: 10.1016/j.vaccine.2020.11.060. Epub 2021 Jan 23. PMID: 33494965.
Avanceña ALV, Prosser LA.
Examining Equity Effects of Health Interventions in Cost-Effectiveness Analysis: A Systematic Review
Value in Health. 2021 Jan;24(1):136-143. doi: 10.1016/j.jval.2020.10.010. Epub 2020 Dec 3. PMID: 33431148.
Defining the value of treatments for rare pediatric conditions (editorial)
JAMA Pediatrics. 2018 Dec 1;172(12):1123-1124. doi: 10.1001/jamapediatrics.2018.3343.
Prosser LA, Lam KK, Grosse SD, Casale M, Kemper AR.
Using decision analysis to support newborn screening policy decisions: A case study for Pompe disease
MDM Policy Pract. 2018 Jan-Jun;3(1). doi: 10.1177/2381468318763814.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG.
Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine
JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.
Wittenberg E, Prosser LA.
Health as a family affair
N Engl J Med. 2016 May 12;374(19):1804-6. doi: 10.1056/NEJMp1604456.
Prosser LA, Lamarand K, Gebremariam A, Wittenberg E.
Measuring family HRQOL spillover effects using direct health utility assessment methods
Med Decis Making. 2015 Jan;35(1):81-93. doi: 10.1177/0272989X14541328.
Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, Zhou F, Dooling K.
A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: Input for national recommendations
Ann Intern Med. 2019 Feb 19. doi: 10.7326/M18-2347. [Epub ahead of print].
Our research team evaluates childhood health interventions using methods of decision sciences and economic evaluation. Current projects use cost-effectiveness analysis, simulation modeling to understand the value of interventions projected over the lifespan. We also use quantitative survey methods, including health utility assessment, conjoint analysis, discrete choice experiments, and best-worst scaling to measure values for health and health interventions. Applied topic areas include vaccination, newborn screening, and rare disorders.